에드로포늄

용도

• Presumptive diagnosis of myasthenia gravis (MG)
• Presumptive diagnosis of myasthenia gravis (MG)
• Presumptive diagnosis of myasthenia gravis (MG)
• Presumptive diagnosis of myasthenia gravis (MG)
• Presumptive diagnosis of myasthenia gravis (MG)
• Presumptive diagnosis of myasthenia gravis (MG)

투여 방법

가능한 부작용

• Urination
• Lacrimation
• Vomiting
• Defecation
• Bradycardia
• Bronchospasm
• Salivation

주의사항 및 금기

• Bronchial asthma
• Mechanical urinary tract obstruction
• Mechanical intestinal tract obstruction
• Known hypersensitivity to the drug
• Use with extreme caution in patients with bradycardias or atrioventricular block. Adequate monitoring and treatment must be available. **Always have IV atropine and an endotracheal tube readily available before administering edrophonium.** Safety during pregnancy is not established (FDA Category C); use only when clearly necessary.

약물 상호작용

• Atropine: Antagonizes the muscarinic effects of edrophonium. Concurrent use should be done cautiously as atropine can mask the early clinical signs of a cholinergic crisis.
• Dexpanthenol: Theoretically may have additive cholinergic effects when used with edrophonium.
• Digoxin: Edrophonium's cardiac effects may be increased; excessive slowing of heart rate (bradycardia) may occur.
• Depolarizing Muscle Relaxants (e.g., succinylcholine, decamethonium): Edrophonium may prolong the Phase I block of these agents.
• Non-depolarizing Muscle Relaxants (e.g., pancuronium, tubocurarine, vecuronium, atracurium): Edrophonium antagonizes the neuromuscular blocking actions of these agents.

자주 묻는 질문